Drugs / Zasocitinib
Trials 24 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT06793943 | Jan → Mar 2025 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT06111547 | Jun → Jul 2024 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT06258265 | Apr → Jun 2024 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT06290050 | Mar → May 2024 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT05992155 | Sep 2023 → May 2024 | impaired renal function disease | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT05976321 | Sep 2023 → Apr 2024 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT05995249 | Aug → Dec 2023 | — | Takeda | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT07403968 | Jul 2026 → Mar 2028 expected | Crohn disease | Takeda | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07244263 | Jan 2026 → Feb 2028 expected | hidradenitis suppurativa | Takeda | Recruiting | No outcome recorded |
| Phase 2 | NCT07108283 | Nov 2025 → Oct 2027 expected | vitiligo | Takeda | Recruiting | No outcome recorded |
| Phase 2 | NCT06764615 | May 2025 → Dec 2029 expected | Crohn disease, ulcerative colitis | Takeda | Recruiting | No outcome recorded |
| Phase 2 | NCT06254950 | Mar 2024 → Sep 2026 expected | ulcerative colitis | Takeda | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06233461 | Mar 2024 → Sep 2026 expected | Crohn disease | Takeda | Recruiting | No outcome recorded |
| Phase 2 | NCT05153148 | Jan 2022 → May 2023 | psoriatic arthritis | Takeda | Completed | No outcome recorded |
| Phase 2 | NCT04999839 | Aug 2021 → Aug 2022 | psoriasis | Takeda | Completed | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT07286058 | Mar 2026 → Dec 2029 expected | psoriatic arthritis | Takeda | Recruiting | No outcome recorded |
| Phase 3 | NCT07250802 | Dec 2025 → Jan 2033 expected | psoriasis | Takeda | Recruiting | No outcome recorded |
| Phase 3 | NCT06973291 | Jul 2025 → Apr 2026 | psoriasis | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT06671496 | Mar 2025 → May 2027 expected | psoriatic arthritis | Takeda | Recruiting | No outcome recorded |
| Phase 3 | NCT06671483 | Mar 2025 → May 2027 expected | psoriatic arthritis | Takeda | Recruiting | No outcome recorded |
| Phase 3 | NCT06550076 | Sep 2024 → Aug 2029 expected | psoriasis | Takeda | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06323356 | Mar 2024 → Oct 2025 overdue | generalized pustular psoriasis | Takeda | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06108544 | Nov 2023 → Dec 2024 | psoriasis | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT06088043 | Nov 2023 → Jan 2025 | psoriasis | Takeda | Completed | No outcome recorded |
Press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-16 | Takeda | Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies takeda.com ↗ |
| 2026-06-11 | Takeda | Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations takeda.com ↗ |
| 2025-12-18 | Takeda | Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment takeda.com ↗ |
| 2023-11-07 | Takeda | Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting takeda.com ↗ |
| 2023-09-11 | Takeda | Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis takeda.com ↗ |
| 2023-03-18 | Takeda | Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis takeda.com ↗ |
| 2022-12-13 | Takeda | Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics takeda.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zasocitinib | “Zasocitinib (TAK-279) is an investigational, once daily, oral, allosteric, highly selective, and potent tyrosine kinase 2 inhibitor.” PMID 42143206 ↗ May 2026 |
| Known as | NDI-034858 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05153148 ↗ |
| Known as | TAK-279 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06258265 ↗ |
| Action | Inhibit | “potent and selective inhibition of TYK2 with zasocitinib” PMID 39167366 ↗ Oct 2024 |
| Modality | Small molecule | — CHEMBL5314423 ↗ |
| Route | Oral | “NDI-034858 oral capsule” NCT05153148 ↗ |
| Target | TYK2 | “potent and selective inhibition of TYK2 with zasocitinib” PMID 39167366 ↗ Oct 2024 |